{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:30:54Z","timestamp":1794486654042,"version":"4.9.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl. Int."],"abstract":"<jats:p>\n                    Low tacrolimus trough concentration-to-dose ratio (CDR) is recognized as an indicator of high tacrolimus metabolism. However, its impact on long-term transplant outcomes and potential for clinical intervention remains unclear. In the largest study to date, we analyzed the impact of a low CDR at post-transplant year 1 on graft loss and patient mortality in 21,865 kidney transplants. We also performed a longitudinal analysis of CDR dynamics and conducted a genetic correlation in a subset of 1,257 patients. Low CDR at year 1 was significantly associated with increased hazards of graft failure (HR up to 2.80) and infection-related mortality (HR = 1.63), even in patients with therapeutic trough levels and good graft function. In the longitudinal analysis, normalizing initially low CDR by year 2 significantly improves graft survival. Low CDR was identified in a substantial proportion of the cohort (25.2%). Black, female, and younger recipients (&amp;lt;50 years) had higher odds of having a low CDR. The\n                    <jats:italic>CYP3A5*1A<\/jats:italic>\n                    genotype was also strongly associated with low CDR (approximately 8-fold higher odds). Patients with a low tacrolimus CDR represent a large high-risk population. The normalization of tacrolimus CDR through co-medication with diltiazem and reductions in steroid dosing may improve graft survival. Our findings support personalized tacrolimus management based on metabolic profiling and genetic testing.\n                  <\/jats:p>","DOI":"10.3389\/ti.2025.15207","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:10:08Z","timestamp":1762150208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hidden in Plain Sight: High Tacrolimus Metabolism Doubles Kidney Transplant Failure and Drives Infection Related Mortality"],"prefix":"10.3389","volume":"38","author":[{"given":"Caner","family":"S\u00fcsal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"D\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erol","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Askar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-Patient Variability in Tacrolimus Exposure: Causes, Consequences for Clinical Management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transpl Rev (Orlando)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1111\/ajt.15346","article-title":"Late Intra-Patient Tacrolimus Trough Level Variability as a Major Problem in Kidney Transplantation: A Collaborative Transplant Study Report","volume":"19","author":"S\u00fcsal","year":"2019","journal-title":"Am J Transpl"},{"key":"B3","unstructured":"CTS Newsletter\n          \n          \n          2014"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-Dependent Variability in Tacrolimus Trough Blood Levels Is a Risk Factor for Late Kidney Transplant Failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High Within-Patient Variability in the Clearance of Tacrolimus Is a Risk Factor for Poor Long-Term Outcome After Kidney Transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transpl"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A High Intrapatient Variability in Tacrolimus Exposure Is Associated with Poor Long-Term Outcome of Kidney Transplantation","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e111128","DOI":"10.1371\/journal.pone.0111128","article-title":"The Tacrolimus Metabolism Rate Influences Renal Function After Kidney Transplantation","volume":"9","author":"Th\u00f6lking","year":"2014","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/tri.13777","article-title":"The Tacrolimus Metabolism Affect Post-Transplant Outcome Mediating Acute Rejection and Delayed Graft Function: Analysis from Korean Organ Transplantation Registry Data","volume":"34","author":"Ro","year":"2021","journal-title":"Transpl Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.intimp.2018.03.004","article-title":"Influence of CYP3A5 Genetic Differences in Tacrolimus on Quantitative Interstitial Fibrosis and Long-Term Graft Function in Kidney Transplant Recipients","volume":"58","author":"Komine","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1201083","DOI":"10.3389\/fphar.2023.1201083","article-title":"Effects of CYP3A4*22 Polymorphism on Trough Concentration of Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-Analysis","volume":"14","author":"Kim","year":"2023","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41397-018-0063-z","article-title":"Identification of Genetic Variants Associated with Tacrolimus Metabolism in Kidney Transplant Recipients by Extreme Phenotype Sampling and next Generation Sequencing","volume":"19","author":"Dorr","year":"2019","journal-title":"Pharmacogenomics J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/ajt.13495","article-title":"Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles","volume":"16","author":"Oetting","year":"2016","journal-title":"Am J Transpl"},{"key":"B13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic Polymorphisms of the CYP3A4, CYP3A5, and MDR-1 Genes and Pharmacokinetics of the Calcineurin Inhibitors Cyclosporine and Tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","article-title":"Impact of Cytochrome p450 3A5 Genetic Polymorphism on Tacrolimus Doses and Concentration-to-Dose Ratio in Renal Transplant Recipients","volume":"76","author":"Thervet","year":"2003","journal-title":"Transplantation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2217\/pgs-2016-0136","article-title":"Consideration of the Ethnic Prevalence of Genotypes in the Clinical Use of Tacrolimus","volume":"17","author":"Andrews","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 Variant Allele Frequencies in Dutch Caucasians","volume":"48","author":"van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic Polymorphism in CYP3A4 Affects Hepatic Expression and Response to Statin Drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trre.2013.01.004","article-title":"The Collaborative Transplant Study Registry","volume":"27","author":"Opelz","year":"2013","journal-title":"Transpl Rev (Orlando)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/jcm8050587","article-title":"Fast Tac Metabolizers at Risk - It Is Time for a C\/D Ratio Calculation","volume":"8","author":"Sch\u00fctte-N\u00fctgen","year":"2019","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/TP.0000000000002920","article-title":"The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-Censored Graft Survival","volume":"104","author":"Jouve","year":"2020","journal-title":"Transplantation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based with Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation","volume":"16","author":"Shuker","year":"2016","journal-title":"Am J Transpl"},{"key":"B24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3389\/fgene.2019.00871","article-title":"The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center","volume":"10","author":"Abdel-Kahaar","year":"2019","journal-title":"Front Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e13162","DOI":"10.1111\/ctr.13162","article-title":"Impact of CYP3A5 Genomic Variances on Clinical Outcomes Among African American Kidney Transplant Recipients","volume":"32","author":"Asempa","year":"2018","journal-title":"Clin Transpl"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1379","DOI":"10.1097\/TXD.0000000000001379","article-title":"Impact of CYP3A5 Status on the Clinical and Financial Outcomes Among African American Kidney Transplant Recipients","volume":"8","author":"Obayemi","year":"2022","journal-title":"Transpl Direct"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/TP.0000000000003871","article-title":"Development of De Novo Donor-Specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype","volume":"106","author":"Friebus-Kardash","year":"2022","journal-title":"Transplantation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.21037\/tau-22-138","article-title":"Carcinogenicity Risk Associated with Tacrolimus Use in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis","volume":"11","author":"Wang","year":"2022","journal-title":"Transl Androl Urol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular Toxicities of Immunosuppressive Agents","volume":"2","author":"Miller","year":"2002","journal-title":"Am J Transpl"},{"key":"B30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/phar.2300","article-title":"Tacrolimus Concentration-to-Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes","volume":"39","author":"Bartlett","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/tpj.2015.87","article-title":"Genotype-Guided Tacrolimus Dosing in African-American Kidney Transplant Recipients","volume":"17","author":"Sanghavi","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/phar.2656","article-title":"Race and Sex Associations with Tacrolimus Pharmacokinetics in Stable Kidney Transplant Recipients","volume":"42","author":"Tornatore","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.genm.2011.01.003","article-title":"Gender Differences in Pharmacokinetics of Tacrolimus and Their Clinical Significance in Kidney Transplant Recipients","volume":"8","author":"Velickovi\u0107-Radovanovi\u0107","year":"2011","journal-title":"Gend Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/jcph.1823","article-title":"Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry","volume":"61","author":"Al-Kofahi","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1463595","DOI":"10.3389\/fphar.2024.1463595","article-title":"Drug-Drug Interaction Between Diltiazem and Tacrolimus in Relation to CYP3A5 Genotype Status in Chinese Pediatric Patients with Nephrotic Range Proteinuria: A Retrospective Study","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"B37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2165\/00002512-200522070-00001","article-title":"Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly","volume":"22","author":"Staatz","year":"2005","journal-title":"Drugs Aging"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.transproceed.2023.09.029","article-title":"Tacrolimus and Diabetes in Kidney Transplantation: The Impact of Cyp3a5 Gene Polymorphism","volume":"55","author":"Liang","year":"2023","journal-title":"Transpl Proc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2147\/TCRM.S129327","article-title":"Genetic Factors in Pathogenesis of Diabetes Mellitus After Kidney Transplantation","volume":"13","author":"Tarnowski","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"B40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/tpj.2014.38","article-title":"Effect of CYP3A5*3 on Kidney Transplant Recipients Treated with Tacrolimus: A Systematic Review and Meta-Analysis of Observational Studies","volume":"15","author":"Rojas","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1046\/j.1523-1755.2001.00030.x","article-title":"International Variation in the Interpretation of Renal Transplant Biopsies: Report of the CERTPAP Project","volume":"60","author":"Furness","year":"2001","journal-title":"Kidney Int"}],"updated-by":[{"DOI":"10.3389\/ti.2025.15860","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000}}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.15207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:34:43Z","timestamp":1765989283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2025.15207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":41,"alternative-id":["10.3389\/ti.2025.15207"],"URL":"https:\/\/doi.org\/10.3389\/ti.2025.15207","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/ti.2025.15207.s001","asserted-by":"subject"}]},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"15207"}}